Twenty-two years of candidaemia surveillance: Results from a Norwegian national study

Clinical Microbiology and Infection

Volumn 21, Issue 10, 2015, Pages 938-945

  Hesstvedt, L ^a   Gaustad, P ^a,b   Andersen, C T ^a   Haarr, E ^c   Hannula, R ^d   Haukland, H H ^e,j   Hermansen, N O ^f   Larssen, K W ^d   Mylvaganam, H ^g   Ranheim, T E ^h   Sandven, P ⁱ   Nordoy I ^a   Kanestrom A ^k   Grub, C ^l   Onken, A ^m   Thielsen, C ⁿ   Skaare, D ^o   Tofteland, S ^p   Sonsteby L J ^q   Hjetland, R ^r   Hide, R ^s   Vik, E ^t   Kummel A ^u   Asheim S ^v   more..

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c STAVANGER UNIVERSITY HOSPITAL   (Norway)

^d TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^f ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^g HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^h AKERSHUS UNIVERSITY HOSPITAL   (Norway)

ⁱ NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^j NORTHERN NORWAY REGIONAL HEALTH AUTHORITY   (Norway)

^k Østfold Hospital Trust   (Norway)

^l INNLANDET HOSPITAL TRUST   (Norway)

^m Vestre Viken Hospital Trust   (Norway)

ⁿ VESTRE VIKEN HOSPITAL TRUST   (Norway)

^o VESTFOLD HOSPITAL TRUST   (Norway)

^p SØRLANDET HOSPITAL   (Norway)

^q Helse Fonna HF   (Norway)

^r Førde Hospital Trust   (Norway)

^s Child Habilitation Unit   (Norway)

^t Molde Hospital   (Norway)

^u Nord Trøndelag Hospital Trust   (Norway)

^v NORDLAND HOSPITAL   (Norway)

more..

Author keywords

Antifungal susceptibility; Candidaemia; Population based incidence; Species distribution; Surveillance

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; VORICONAZOLE; ANTIFUNGAL AGENT;

ADOLESCENT; ADULT; AGE; AGED; ANTIBIOTIC RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BLOOD CULTURE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CHILD; CLAVISPORA LUSITANIAE; FEMALE; FUNGUS ISOLATION; HUMAN; INCIDENCE; INFANT; MALE; MEYEROZYMA GUILLIERMONDII; NEWBORN; NONHUMAN; NORWAY; PICHIA KUDRIAVZEVII; PRIORITY JOURNAL; SPECIES DISTRIBUTION; ANTIFUNGAL RESISTANCE; CANDIDA; CLASSIFICATION; DRUG EFFECTS; EPIDEMIOLOGICAL MONITORING; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PRESCHOOL CHILD; PROSPECTIVE STUDY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDA; CANDIDEMIA; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, FUNGAL; EPIDEMIOLOGICAL MONITORING; FEMALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NORWAY; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84942196040     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2015.06.008     Document Type: Article

References (30)

1. Pfaller M.A., Diekema D.J. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007, 20:133-163.
2. Zaoutis T.E., Argon J., Chu J., Berlin J.A., Walsh T.J., Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005, 41:1232-1239.
3. Horn D.L., Neofytos D., Anaissie E.J., Fishman J.A., Steinbach W.J., Olyaei A.J., et al. Epidemiology and outcomes of candidemia in 2019 Patients: Data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009, 48:1695-1703.
4. Monatgna M.T., Lovero G., Borghi E., Amato G., Andreoni S., Campion L., et al. Candidemia in intensive care unit: a nationwide prospective observational survey (GISIA-3 study) and review of the European literature from 2000 through 2013. Eur Rev Med Pharmacol Sci 2014, 18:661-674.
5. Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., Edmond M.B. Nosocomial bloodstream infections in US hospitals: analysis of 24.179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004, 39:309-317.
6. Marchetti O., Bille J., Fluckinger U., Eggiman P., Ruef C., Garbino J., et al. Epidemiology of candidemia in Swiss tertiary care hospitals: Secular trends, 1991-2000. Clin Infect Dis 2004, 38:311-320.
7. Almirante B., Rodriguez D., Park BJl, Cuenca-Estrella M., Planes A.N., et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005, 43:1829-1835.
8. Ásmundsdóttir L.R., Erlendsdóttir H., Gottfredsson M. Increasing incidence of candidemia: Results from a 20-year nationwide study in Iceland. J Clin Microbiol 2002, 40:3489-3492.
9. Sandven P., Bevanger L., Digranes A., Haukland H.H., Mannsåker T., Gaustad P., et al. Candidemia in Norway (1991 to 2003): results from a nationwide study. J Clin Microbiol 2006, 44:1977-1981.
10. Sandven P., Bevanger L., Digranes A., Gaustad P., Haukland H.H., Steinbakk M., et al. Constant low rate of fungemia in Norway, 1991 to 1996. J Clin Microbiol 1998, 36:3455-3459.
11. Poikonen E., Lyytikäinen O., Anttila V.J., Ruutu P. Candidemia in Finland, 1995-1999. Emerg Infect Dis 2003, 9:985-990.
12. Ericsson J., Chryssanthou E., Klingspor L., Johansson A.G., Ljungman P., Svensson E., et al. Candidaemia in Sweden: a nationwide prospective observational survey. Clin Microbiol Infect 2013, 19:218-221.
13. Poikonen E., Lyytikainen O., Atilla V.J., Koivula J., Lumio J., Kotilainen P., et al. Secular trend in candidemia and the use of fluconazole in Finland, 2004-2007. BMC Infect Dis 2010, 10:312-318.
14. Arendrup M.C., Dzajic E., Jensen R.H., Johansen H.K., Kjaeldgaard P., Knudsen J.D., et al. Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: Data from a nationwide fungaemia surveillance programme. Clin Microbiol Infect 2013, 19:343-353.
15. Nucci M., Queiroz-Telles F., Alvarado-Matute T., Tiraboshi I.N., Cortes J., Zurita J., et al. Epidemiology of candidemia in Latin America: a laboratory-based survey. PLoS ONE 2013, 8:1-7.
16. Guinea J. Global trends in the distribution of Candida species causing candidemia. Clin Microbiol Infect 2014, 20:5-10.
17. Pfaller M.A., Messer S.A., Moet G.J., Jones R.N., Castanheira M. Candida bloodstream infections: Comparison of species distribution and resistance to echinocandin and azole antifungal agents in intensive care unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009). Int J Antimicrob Agents 2011, 38:65-69.
18. Guimaraes T., Nucci M., Mendonca J.S., Martinez R., Brito L.R., Silva N., et al. Epidemiology and predictors of a poor outcome in elderly patients with candidemia. Int J Infect Dis 2012, 16:442-447.
19. Arendrup M.C., Fuursted K., Garhn-Hansen B., Jensen I.M., Knudsen J.D., Lundgren B., et al. Seminational surveillance of fungemia in Denmark: Notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. J Clin Microbiol 2005, 43:4434-4440.
20. Horvath L.L., George B.J., Murray C.K., Harrison L.S., Hospenthal D.R. Direct comparison of the BACTEC 9240 and BacT/ALERT 3D automated blood culture systems for Candida growth detection. J Clin Microbiol 2004, 42:115-118.
21. Jekarl D.W., Lee S.Y., Lee S., Park Y.J., Lee J., Baek S.M., et al. Comparison of the Bactec Fx Plus, Mycosis IC/F, Mycosis/F Lytic blood culture media and the BacT/Alert 3D FA media for detection of Candida species in seeded blood culture specimens containing therapeutic peak levels of fluconazole. J Clin Lab Anal 2012, 26:412-419.
22. Cleveland A.A., Harrison L.H., Farley M.M., Hollick R., Stein B., Chiller T.M., et al. Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008-2013: results from population-based surveillance. PLoS ONE 2015, 10:1-12.
23. Odds F.C., Hanson M.F., Davidson A.D., Jacobsen M.D., Wright P., Whyte J.A., et al. One year prospective survey of Candida bloodstream infections in Scotland. J Med Microbiol 2007, 56:1066-1075.
24. Bassetti M., Merelli M., Righi E., et al. Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia across five sites in Italy and Spain. J Clin Microbiol 2013, 51:4167-4172.
25. Arendrup M.C. Candida and candidemia. Susceptibility and epidemiology. Dan Med J 2013, 60:1-32.
26. Marcos-Zambrano L.J., Escribano P., Sánchez C., Muñoz P., Bouza E., Guinea J. Antifungal resistance to fluconazole and echinocandins is not emerging in yeast isolates causing fungemia in a Spanish tertiary care center. Antimicrob Agents Chemother 2014, 58:4565-4572.
27. Alexander B.D., Johnesen M.D., Pfeiffer C.D., Jimenez-Ortigosa C., Catania J., Booker R., et al. Increasing echinocandin resistance in Candida glabrata: Clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 2013, 56:1724-1732.
28. Reboli A.C., Rotstein C., Pappas P.G., Chapman S.W., Kett D.H., Kumar D., et al. Anidulafungin versus fluconazole for invasive candidasis. N Engl J Med 2007, 356:2472-2482.
29. Arendrup M.C., Cuenca-Estrella M., Lass-Flörl C., Hope W.W. Breakpoints for antifungal agents: An update from EUCAST focusing on echinocandins against Candida spp. and triazoles against Aspergillus spp. Drug Resist Update 2013, 16:81-95.
30. Clinical and Laboratory Standard Institute Reference method for broth dilution antifungal susceptibility testing of yeast: 4h Informational Supplement, M27-S4 2012, CLSI, Wayne, PA.